Coleman CI, et al. - Using MarketScan claims data, researchers contemplated the effectiveness and safety of rivaroxaban compared with warfarin for treatment of venous thromboembolism (VTE) in patients with known primary hypercoagulable states (PHSs). They also compared the rates of recurrent VTE and major bleeding. During this study, rivaroxaban and warfarin users were 1:1 propensity-score matched. In contrast with warfarin, a connection was illustrated between rivaroxaban use with a non-significant reduction in recurrent VTE and major bleeding. Yielded data disclosed similar effectiveness and safety of rivaroxaban versus warfarin in VTE patients with a known PHS in routine practice to that observed in the EINSTEIN trial program.